Literature DB >> 111274

Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

S Lipper, D L Murphy, S Slater, M S Buchsbaum.   

Abstract

The antidepressant and other behavioral effects of clorgyline, a preferential inhibitor of monoamine oxidase (MAO) type A, were compared with those of pargyline, a preferential inhibitor of MAO type B, in 16 depressed patients. In a subgroup of more severely depressed patients, clorgyline treatment for 4 weeks resulted in significant improvement on both observer-rated and self-rated scales, while minimal changes occurred during pargyline treatment. Similarly, in a crossover study that included 8 patients examined with multiple scales, clorgyline had generally greater antidepressant and antianxiety effects than did pargyline, although pargyline had some activating effects and also tended to produce more side effects. MAO type A inhibition may be more important than MAO type B inhibition for antidepressant efficacy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111274     DOI: 10.1007/bf00427124

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

Review 1.  Multiple forms of monoamine oxidase: fact and artefact.

Authors:  M D Houslay; K F Tipton
Journal:  Life Sci       Date:  1976-08-15       Impact factor: 5.037

Review 2.  The behavioral toxicity of monoamine oxidase-inhibiting antidepressants.

Authors:  D L Murphy
Journal:  Adv Pharmacol Chemother       Date:  1977

3.  Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline.

Authors:  J C SAUNDERS
Journal:  Ann N Y Acad Sci       Date:  1963-07-08       Impact factor: 5.691

4.  Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase.

Authors:  C H Donnelly; D L Murphy
Journal:  Biochem Pharmacol       Date:  1977-05-01       Impact factor: 5.858

Review 5.  Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences.

Authors:  D L Murphy
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

Review 6.  The sensation seeking motive.

Authors:  M Zuckerman
Journal:  Prog Exp Pers Res       Date:  1974

7.  Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo.

Authors:  D S Robinson; W Lovenberg; H Keiser; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

8.  Monamine oxidase in schizophrenia and other behavioral disorders.

Authors:  D L Murphy; R Belmaker; R J Wyatt
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

9.  Comparative trial of a new mono-amine oxidase inhibitor in depression.

Authors:  D Wheatley
Journal:  Br J Psychiatry       Date:  1970-11       Impact factor: 9.319

10.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06
View more
  28 in total

1.  Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.

Authors:  D L Murphy; S Lipper; S Slater; D Shiling
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

2.  Possible melatonin involvement in the hypotensive effect of MAO inhibitors.

Authors:  G F Oxenkrug; R B McCauley; D J Fontana; I M McIntyre; R L Commissaris
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

3.  Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior.

Authors:  G J Marek; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

Authors:  A Prasad; V Glover; B L Goodwin; M Sandler; M Signy; S E Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.

Authors:  K White; J Razani; B Cadow; R Gelfand; R Palmer; G Simpson; R B Sloane
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 6.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

9.  Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.

Authors:  N A Garrick; T Seppala; M Linnoila; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Monoamine oxidase (MAO) activity as a determinant in human neurophysiology.

Authors:  J E Pintar; X O Breakefield
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.